



NanoEcho increases global presence in the ultrasound industry

NanoEcho AB participates in the international ultrasound conference, the IEEE International Ultrasonics Symposium (IUS), together with one of the company's key suppliers, us4us Ltd. Attendance at the conference is a strategic step toward establishing NanoEcho's presence in the global ultrasound market.

NanoEcho is participating together with us4us Ltd., a leading provider of ultrasound technology, at the international ultrasound conference, the IEEE International Ultrasonics Symposium (IUS) in Montreal, Canada. The conference brings together exhibitors, sponsors, and partners worldwide to exchange knowledge and participate in discussions around the latest advances in ultrasound technology.

NanoEcho's participation in the conference with us4us strengthens NanoEcho's position in medical ultrasound diagnostics. The companies have previously signed letters of intent regarding developing an innovative medical ultrasound scanner module for diagnostics.

“Our participation provides a strategically important opportunity for NanoEcho to increase our global presence in the ultrasound industry. By doing this together with us4us, we strengthen our visibility among key personnel and technical innovators in the industry”, says Linda Persson, CEO of NanoEcho.

“Our mutual display at this important ultrasound scientific conference shows our strong collaboration and benefits of the joint development”, says Marcin Lewandowski, CEO of us4us Ltd.

For further information, please contact:

Kristina Hallström, CMO & CCO
email: ir@nanoecho.se

Press Release
06 September 2023 15:45:00 CEST



NANO ECHO
next level diagnostics

NanoECHO develops a new technology for clearer diagnostics of, in the first indication, rectal cancer. The imaging technology is based on a new medical approach where nanotechnology is used in combination with modern patented ultrasound technology. The images that are generated are intended to facilitate differentiation between healthy and diseased tissue and at the same time determine the location of the cancer tissue more precisely. The aim is to provide more precise, simple, and cost-effective diagnosis of cancers and other diseases. With clearer diagnostics, the company wants to assist treating physicians with better guidance for more personalised treatment. Both the quality of life of the patients and their chance of survival can improve after treatment, with reduced treatment costs. www.nanoecho.se